Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

被引：0
|
作者：
Thomas E. Stinchcombe
Mark A. Socinski
Christine M. Walko
Bert H. O’Neil
Frances A. Collichio
Anastasia Ivanova
Hua Mu
Michael J. Hawkins
Richard M. Goldberg
Celeste Lindley
E. Claire Dees
机构：
[1] University of North Carolina,Department of Hematology/Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center
[2] University of North Carolina,School of Pharmacy
[3] Lineberger Comprehensive Cancer Center,Department of Biostatics
[4] Abraxis BioScience,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Dose-limiting toxicity; Maximum tolerated dose; Melanoma; Non-small-cell lung cancer; Small-cell lung cancer; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 766
页数：7
相关论文
共 50 条
  • [1] Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
    Stinchcombe, Thomas E.
    Socinski, Mark A.
    Walko, Christine M.
    O'Neil, Bert H.
    Collichio, Frances A.
    Ivanova, Anastasia
    Mu, Hua
    Hawkins, Michael J.
    Goldberg, Richard M.
    Lindley, Celeste
    Dees, E. Claire
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 759 - 766
  • [2] Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
    Miele, Evelina
    Spinelli, Gian Paolo
    Miele, Ermanno
    Tomao, Federica
    Tomao, Silverio
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2009, 4 (01): : 99 - 105
  • [3] Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
    Yamada, Kazuhiko
    Yamamoto, Noboru
    Yamada, Yasuhide
    Mukohara, Toru
    Minami, Hironobu
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (05) : 404 - 411
  • [4] Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma
    Altundag, Kadri
    Dede, Didem S.
    Purnak, Tugrul
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (08) : 958 - 958
  • [5] A phase I study of the mTOR inhibitor sirolimus (rapamycin) in combination with nanoparticle albumin-bound paclitaxel (ABI-007, abraxane) in advanced solid cancers
    Abu-Khalaf, Maysa
    Gettinger, Scott
    Lansigan, Frederick
    Klutenaar, Jeannie
    Clark, Mary Beth
    Thomas, Laurie
    Doddamane, Indu
    Kelly, William Kevin
    Rimm, David
    Schwartz, Peter
    Harris, Lyndsay
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3575S - 3576S
  • [6] Phase I trial of escalating doses of ABI-007 (nanoparticle albumin-bound paclitaxel) and gemcitabine in patients (pts) with thoracic malignancies
    Lee, C. B.
    Stinchcombe, T. E.
    Socinski, M. A.
    Hayes, D. N.
    Goldberg, R. M.
    Hawkins, M. J.
    Obasaju, C. K.
    Dees, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
    Ibrahim, NK
    Samuels, B
    Page, R
    Doval, D
    Patel, KM
    Rao, SC
    Nair, MK
    Bhar, P
    Desai, N
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6019 - 6026
  • [8] ABI-007, nanoparticle albumin-bound paclitaxel, enhances tumor radioresponse.
    Mason, Kathy A.
    Wiedenmann, Nicole
    Valdecanas, David
    Buchholz, Thomas
    Milas, Luka
    CANCER RESEARCH, 2006, 66 (08)
  • [9] In vivo radiation enhancement by ABI-007, a nanoparticle albumin-bound (nab) paclitaxel
    Wiedenmann, N.
    Valdecanas, D.
    Farrar, D.
    Milas, L.
    Mason, K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 13 - 14
  • [10] Automated quantitative analysis of AKT/mTOR pathway in patients treated with nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) and (sirolimus) Rapamycin
    Abu-Khalaf, M. M.
    Moeder, C.
    Gettinger, S.
    Rimm, D.
    Harris, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345